International Hepatology

Dr. Lai Wei: Currently, two-thirds of global viral hepatitis cases are concentrated in Asia, with about half occurring in China. The World Health Organization (WHO) aims to reduce new viral hepatitis infections by 90% and related mortality by 65% by 2030. Thus, contributions from the Asia-Pacific region are pivotal in achieving these elimination goals.

Liver cancer remains one of the deadliest malignancies worldwide, with China carrying a significant burden of cases. Understanding the unique epidemiology, molecular characteristics, and treatment strategies across different regions is crucial for advancing patient outcomes. In an exclusive cross-border dialogue, Professor Qin Shukui of Nanjing Tianyin Mountain Hospital, China, and Professor Pablo Sarobe of the University of Navarra Medical School, Spain, share their insights into the latest breakthroughs in liver cancer treatment. They discuss the evolving role of immunotherapy, targeted therapy, and the importance of global collaboration in shaping the future of liver cancer care. Watch the full conversation to gain expert perspectives on emerging treatment strategies, biomarker-driven approaches, and the future of liver cancer therapy.

Editorial Note: Transjugular intrahepatic portosystemic shunt (TIPS) is an effective intervention for managing complications of portal hypertension in cirrhosis, such as refractory ascites or secondary prevention of esophageal and gastric…

Editorial Note: Metabolic dysfunction-associated steatohepatitis (MASH) has emerged as a leading cause of chronic liver disease worldwide. With the increasing prevalence of obesity and type 2 diabetes, the incidence of…

Editor’s Note: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-quarter of the global adult population, imposing a significant health and economic burden. However, there are currently no approved treatments…

Cirrhotic patients with clinically significant portal hypertension (CSPH) often develop refractory ascites. Transjugular intrahepatic portosystemic shunt (TIPS) is a well-established treatment for CSPH, but it carries a substantial risk of…

Editorial Note: Metabolic-associated steatohepatitis (MASH) is a subtype of metabolic-associated fatty liver disease (MASLD), characterized by hepatic steatosis, lobular inflammation, and hepatocellular ballooning, with a high risk of progressing to…

From February 20 to 22, 2025, the European Association for the Study of the Liver (EASL) hosted the Liver Cancer Summit in Paris, France. During this prestigious academic event, our…

Editorial Note: Hepatitis B virus (HBV) infection is a global public health challenge, causing nearly a million deaths annually due to complications such as liver failure, cirrhosis, and hepatocellular carcinoma.…

Editorial Note: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 32% of the global population. Without proper intervention, it can progress to metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, cirrhosis, and…